Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Lometrexol may stop or slow the growth of tumor cells by blocking the enzymes
necessary for tumor cell growth. Folic acid may be effective in preventing or lessening the
side effects of lometrexol. Combining lometrexol with folic acid may be an effective
treatment for non-small cell lung cancer.
PURPOSE: Phase II trial to study the effectiveness of combining lometrexol with folic acid in
treating patients who have stage IIIB or stage IV non-small cell lung cancer that has been
previously treated.
Phase:
Phase 2
Details
Lead Sponsor:
Tularik
Treatments:
Folic Acid Lometrexol Tetrahydrofolates Vitamin B Complex